Pfizer’s bivalent coronavirus booster has been found to increase the risk of ischemic strokes among people over 65, but, a new CDC report found, the risk is small and may be associated with receiving a flu shot at the same time as the booster. The company said last month that it is shutting down most of its efforts to find therapies for early-stage rare diseases in neurology and cardiopathy and programs in gene therapy. The company did not indicate the size of any cost savings.
Of 24 analysts, 14 rate the stock at Hold and 10 have a Buy or Strong Buy rating. At a share price of around $44.00, the upside potential based on a median price target of $52.65 is nearly 20%. At the high target of $75, the upside potential is 70.5%.
Fourth-quarter revenue is forecast at $24.6 billion, up 8.7% sequentially and by 3.2% year over year. Adjusted EPS are pegged at $1.07, down 40.1% sequentially and down a penny year over year. For the full 2022 fiscal year, analysts expect Pfizer to report EPS of $6.49, up 46.9%, on sales of $100.5 billion, up 23.6%.
Pfizer stock trades at 6.8 times expected 2022 EPS, 9.9 times estimated 2023 earnings of $4.44 and 10.8 times estimated 2024 earnings of $7.08 per share. The stock’s 52-week range is $41.45 to $56.32. Pfizer pays an annual dividend of $1.64 (yield of 3.71%). Total shareholder return for the past 12 months was negative at 14.37%.
UPS
United Parcel Service Inc. (NYSE: UPS) stock has added about 4.6% over the past 12 months, including a plunge of more than 9% in the past three months. While worries about macroeconomic issues, particularly growth, dog the company, UPS’s two-year focus on small and medium-sized business deliveries, health care, international shipping and business-to-business e-commerce has been paying off. Earnings growth may be tapering, but UPS’s customer base is solid and unlikely to run off to a competitor.
Analysts remain somewhat bullish on the stock, with 15 of 30 having a Buy or Strong Buy rating and 12 others rating it at Hold. At a share price of around $182.00, the upside potential based on a median price target of $191.50 is 5.2%. At the high price target of $227.00, the upside potential is 24.7%.
Analysts expect UPS to report fourth-quarter revenue of $28.03 billion, up 16.0% sequentially and up 0.9% year over year. Adjusted EPS are pegged at $3.59, up 20% sequentially and flat year over year. For the full 2022 fiscal year, analysts are looking for EPS of $12.91, up 6.4%, on sales of $101.3 billion, up 4.1%.
UPS stock trades at 14.1 times expected 2022 EPS, 15.1 times estimated 2023 earnings of $12.10 and 14.3 times estimated 2024 earnings of $12.73 per share. The stock’s 52-week range is $154.87 to $233.72. UPS pays an annual dividend of $6.08 (yield of 3.38%). Total shareholder return for the past 12 months was negative 3.3%.
Originally published at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
